MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers - a phase I clinical trial
Favorite
Share
More Options
10

Open in WPS to view all 10 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
